Researchers studied 69 patients with muscle-invasive bladder cancer who had undergone complete surgical removal of visible tumors. The goal was to see if adding the drug gemcitabine to cisplatin-based radiotherapy improved outcomes compared to cisplatin alone. This approach aims to preserve the bladder organ while treating the cancer effectively.
The main result showed that adding gemcitabine did not improve 2-year disease-free survival. The rates were 58.3% for cisplatin alone and 60.0% for the combination therapy. While overall survival rates varied slightly at different time points, the study did not prove that the extra drug offered a clear benefit for keeping the disease away.
Safety profiles were generally comparable, though patients receiving gemcitabine experienced more blood cell issues known as cytopenias. The study faced significant limitations, including early termination and insufficient numbers of participants. Readers should understand that this early evidence is uncertain and does not yet support changing current medical practices for this condition.